PL3045183T3 - Pegylowana apelina i jej zastosowania - Google Patents

Pegylowana apelina i jej zastosowania

Info

Publication number
PL3045183T3
PL3045183T3 PL16155181T PL16155181T PL3045183T3 PL 3045183 T3 PL3045183 T3 PL 3045183T3 PL 16155181 T PL16155181 T PL 16155181T PL 16155181 T PL16155181 T PL 16155181T PL 3045183 T3 PL3045183 T3 PL 3045183T3
Authority
PL
Poland
Prior art keywords
pegylated apelin
apelin
pegylated
Prior art date
Application number
PL16155181T
Other languages
English (en)
Inventor
Zhiqiang JIA
HOU Lihui
Clark Q. Pan
Geoffrey Y. Akita
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of PL3045183T3 publication Critical patent/PL3045183T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL16155181T 2011-03-11 2012-03-08 Pegylowana apelina i jej zastosowania PL3045183T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161451623P 2011-03-11 2011-03-11
EP16155181.7A EP3045183B1 (en) 2011-03-11 2012-03-08 Pegylated apelin and uses thereof
EP12757055.4A EP2683360B1 (en) 2011-03-11 2012-03-08 Pegylated apelin and uses thereof

Publications (1)

Publication Number Publication Date
PL3045183T3 true PL3045183T3 (pl) 2018-12-31

Family

ID=46831054

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12757055.4T PL2683360T3 (pl) 2011-03-11 2012-03-08 Pegylowana apelina i jej zastosowania
PL16155181T PL3045183T3 (pl) 2011-03-11 2012-03-08 Pegylowana apelina i jej zastosowania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL12757055.4T PL2683360T3 (pl) 2011-03-11 2012-03-08 Pegylowana apelina i jej zastosowania

Country Status (14)

Country Link
US (1) US20140142049A1 (pl)
EP (2) EP2683360B1 (pl)
AU (2) AU2012229336B2 (pl)
CA (1) CA2829693C (pl)
CY (1) CY1117654T1 (pl)
DK (2) DK3045183T3 (pl)
ES (2) ES2690147T3 (pl)
HR (2) HRP20160547T1 (pl)
HU (1) HUE027579T2 (pl)
LT (1) LT3045183T (pl)
PL (2) PL2683360T3 (pl)
PT (1) PT3045183T (pl)
SI (2) SI2683360T1 (pl)
WO (1) WO2012125408A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3045183T (pt) 2011-03-11 2018-11-02 Genzyme Corp Apelina peguilada e suas utilizações
EP3907237A1 (en) * 2012-12-20 2021-11-10 Amgen Inc. Apj receptor agonists and uses thereof
EA201591700A1 (ru) 2013-03-14 2015-12-30 Ридженерон Фармасьютикалз, Инк. Гибридные белки апелина и их применение
EP3024847A1 (en) * 2013-07-25 2016-06-01 Novartis AG Disulfide cyclic polypeptides for the treatment of heart failure
WO2015013169A2 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
EP3024845A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
WO2015013165A1 (en) * 2013-07-25 2015-01-29 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure
CA2931299C (en) 2013-11-20 2024-03-05 Regeneron Pharmaceuticals, Inc. Aplnr modulators and uses thereof
DK3122764T3 (en) 2014-03-25 2019-04-15 Lanthiopep Bv CYCLIC APELINE ANALOGS
US10941182B2 (en) * 2014-06-10 2021-03-09 Amgen Inc. Apelin polypeptides
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
CN110072531A (zh) 2016-10-19 2019-07-30 阿维夫公司 用于治疗心血管相关疾病的爱帕琳的新型聚乙二醇化的脂质体制剂
US20230226231A1 (en) * 2020-06-18 2023-07-20 Universite D'aix Marseille Conjugated and labelled apelin, preparation and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
DE602004027798D1 (de) * 2003-03-12 2010-08-05 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
US7947280B2 (en) * 2003-05-22 2011-05-24 The Board Of Trustees Of The Leland Stanford Junior University Apelin and uses thereof
EP1922336B1 (en) * 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
PT3045183T (pt) 2011-03-11 2018-11-02 Genzyme Corp Apelina peguilada e suas utilizações

Also Published As

Publication number Publication date
DK3045183T3 (en) 2018-10-22
EP2683360A4 (en) 2014-09-03
WO2012125408A1 (en) 2012-09-20
EP3045183B1 (en) 2018-07-04
HRP20160547T1 (hr) 2016-06-17
CY1117654T1 (el) 2018-03-07
HUE027579T2 (en) 2016-10-28
ES2690147T3 (es) 2018-11-19
EP2683360B1 (en) 2016-02-24
AU2017202919A1 (en) 2017-05-25
DK2683360T3 (en) 2016-05-30
AU2017202919B2 (en) 2019-03-14
ES2573337T3 (es) 2016-06-07
CA2829693C (en) 2020-04-21
PT3045183T (pt) 2018-11-02
LT3045183T (lt) 2018-10-25
EP3045183A1 (en) 2016-07-20
AU2012229336B2 (en) 2017-02-02
HRP20181589T1 (hr) 2018-12-28
US20140142049A1 (en) 2014-05-22
SI2683360T1 (sl) 2016-06-30
WO2012125408A8 (en) 2018-01-25
CA2829693A1 (en) 2012-09-20
SI3045183T1 (sl) 2018-11-30
EP2683360A1 (en) 2014-01-15
PL2683360T3 (pl) 2016-09-30
AU2012229336A1 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
HRP20181589T1 (hr) Pegilirani apelin i njegova upotreba
IL233051A0 (en) Anti-phf-tau antibodies and uses thereof
DK2729170T3 (en) Antibody variants and uses thereof
IL229844B (en) Anti-psgl-1 antibodies and their use
IL230511A0 (en) 4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors
IL221768A (en) From women
GB201110783D0 (en) Methods and uses
ZA201401210B (en) Peptide nanoparticles and uses thereof
GB201116774D0 (en) Uses and methods
SG11201402139UA (en) High mast2-affinity polypeptides and uses thereof
EP2716359A4 (en) COMPLEX AND USES THEREOF
GB201108490D0 (en) Methods and uses
GB201111722D0 (en) Game arrangement
GB201119443D0 (en) GoWinging Concept and patent
PT2734522T (pt) 4-imidazopiridazina-1-il-benzamidas e 4-imidazotriazin-1- il-benzamidas como inibidores de btk
GB201117881D0 (en) Biomarkers and uses thereof
GB201113314D0 (en) Formulations and processes
GB201009551D0 (en) Game
GB201013800D0 (en) Game
GB201012945D0 (en) Kerbee game
GB201120454D0 (en) Kit and uses thereof
GB201006417D0 (en) Copernisis puzzle
GB201003839D0 (en) 3deeko puzzle